Psoriasis Area and Severity Index response in moderate‐severe psoriatic patients switched to adalimumab: results from the <scp>OPPSA</scp> study

Talamonti, Mark S.; Galluzzo, Marco; Bernardini, Nicoletta; Caldarola, Giacomo; Persechino, Severino; Cantoresi, Franca; Egan, Colin Gerard; Potenza, Concetta; Peris, Ketty; Bianchi, Luca

doi:10.1111/jdv.15077

Cited by 17 publications

(20 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the reasons for this association are not yet clear, anti-TNF-a and IL-17 biologics have shown reduced efficacy in patients with a higher body mass index (13,24). In addition, the presence of concomitant metabolic syndrome is associated with lower rates of PASI response in patients treated with adalimumab and secukinumab (12,13). Anti-TNF-a therapies are associated with weight gain in patients with psoriasis, and may thus potentially exacerbate metabolic conditions (25).…”

Section: Discussionmentioning

confidence: 99%

“…However, the overlap between the pathogenetic mechanisms of psoriasis and metabolic syndrome suggests that patients with metabolic syndrome or individual metabolic conditions may respond differently to these psoriasis treatments, which could possibly affect their efficacy and safety in this subpopulation (11). Although few data on the effects of biologic treatments in patients with metabolic syndrome are available, studies are beginning to indicate that the presence of metabolic syndrome may reduce the rate of Psoriasis Area and Severity Index (PASI) response following treatment with anti-TNF-a and IL-17 agents (12,13). In addition, psoriasis patients with metabolic syndrome have reduced long-term drug survival of biologic treatments, including adalimumab, etanercept, secukinumab, and ustekinumab (14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status

Feldman

Zhang

Martínez

et al. 2019

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Objectives: To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast. Methods: Adult patients included had !1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and 08/31/2018 (date of first prescription was index date) and no index drug use in the 12-months pre-index, and continuous enrollment in the 12-month pre-index and 24-month post-index periods. Patients were divided into mutually exclusive treatment cohorts and stratified by their pre-index metabolic condition status. Treatment patterns (adherence, non-persistence, switching, discontinuation, use of combination therapy, and re-initiation) and healthcare costs were compared. Results: Overall, 7773 patients were included; 47.5-56.7% had a metabolic condition. Except for the apremilast group, patients with metabolic conditions had higher discontinuation (secukinumab: 50.6% vs. 43.7%; adalimumab Ã : 53.9% vs. 48.7%; ustekinumab Ã : 41.9% vs. 35.1%; etanercept: 42.8% vs. 41.2%; apremilast: 43.1% vs. 46.1%) and switching (secukinumab: 48.1% vs. 41.2%; adalimumab Ã : 47.8% vs. 41.9%; ustekinumab Ã : 34.5% vs. 25.3%; etanercept Ã : 53.6% vs. 51.5%; apremilast: 45.8% vs. 44.6%) than patients without (Ã p < .05). Patients with metabolic conditions incurred significantly higher costs. Conclusion: Many psoriasis patients initiating biologics or apremilast had metabolic conditions. These patients had higher discontinuation and switching, and significantly higher healthcare costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status

Feldman

Zhang

Martínez

et al. 2019

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…In a 52‐week, multi‐center, randomized controlled phase 3 study evaluating the efficacy of adalimumab, the PASI75 response rate was 71% at 16th weeks 20 . In OPPSA study, PASI50, PASI75, PASI90, PASI100 responses' rates were; 88.6%, 49.8%, 32.5%, 21.2% at week 12, 92.5%, 79%, 56%, 48.4% at week 24, 91.6%, 83.7%, 62.8%, 57.6% at week 48, respectively 21 . Compared to these studies, our study has higher rates in PASI50 and PASI75 responses and lower rates in PASI90 and PASI100 responses (Table 6).…”

Section: Discussionmentioning

confidence: 96%

Retrospective analysis of patients with psoriasis receiving biological therapy: Real‐life data

Özçelik

Kılıç

Başara

2020

Dermatologic Therapy

View full text Add to dashboard Cite

The aim of this study is to investigate the demographic and clinical characteristics of patients receiving biological therapy for psoriasis. All patients who received biological treatment for psoriasis were included in the study. Characteristics of patients and PASI responses' rates were evaluated at 6, 12, 16, 24, 36, and 52 weeks. One hundred and three patients enrolled. Of all, 28 patients were using adalimumab (27.2%), 26 were using secukinumab (25.2%), 22 were using infliximab (21.4%), 22 were using ustekinumab (21.4%), 5 were using ixekizumab (4.9%). PASI75 response rates at sixth and 52nd weeks; were 68.1% and 95% for infliximab, 64.3% and 100% for adalimumab, 77.3% and 100% for ustekinumab, 76.9% and 81.3% for secukinumab, respectively. The most common reason for biologic switching was secondary failure. Treatment failure was the main reason of switching therapies. In our study, no statistically significant difference was found between efficacies of biological drugs. It remains unclear in what order and how exactly biological agent switching should be done. There is a need for large-scale studies on the treatment response rates, and survival times of different biologics.

show abstract

“…Thus, it is important to find genetic biomarkers that could help to determine which treatment is better for each patient. Although the pharmacogenetic basis of biological drug response has been widely studied in candidate‐gene studies, 8,16–38 to our knowledge, there is only one publication that carried out a pharmacogenomic study in psoriasis following a hypothesis‐free approach 39 . This study ( n = 65) failed to find biomarkers predictive of drug response in a Japanese cohort of patients 39 .…”

Section: Introductionmentioning

confidence: 98%

Genome‐wide association analysis of psoriasis patients treated with anti‐TNF drugs

Ovejero‐Benito

Muñoz‐Aceituno

Sabador

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

While anti-TNF therapies are effective against psoriasis, 30%-50% of patients do not show an adequate response to these drugs. Different candidate-gene pharmacogenetics studies have identified single nucleotide polymorphisms that may predict anti-TNF drugs response in psoriasis. Nevertheless, only one paper has undertaken a pharmacogenomic approach failing to find significant biomarkers of biological drug response along the whole genome. Furthermore, most of the pharmacogenetic candidate biomarkers identified previously have not been confirmed in a different cohort of patients. The objective of this study was to find biomarkers that could predict anti-TNF drugs response along the whole genome and validate biomarkers identified previously. A genome-wide association study (GWAS) was performed using the Human Omni Express-8 v1.2 Beadchips in 243 psoriasis patients treated with anti-TNF drugs. This study was multicentric and did not interfere with clinical practice. Associations between single nucleotide polymorphisms (SNP) and PASI75 (a 75% reduction with respect to baseline PASI) at 3 months were evaluated. Imputation was performed using SNPs with R 2 > 0.7. There were two SNPs located in NPFFR2 that were close to the significant threshold of 5 × 10 −8. These data suggest that NPFFR2 might be associated with anti-TNF drug response. However, further How to cite this article: Ovejero-Benito MC, Muñoz-Aceituno E, Sabador D, et al. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.

show abstract

Psoriasis Area and Severity Index response in moderate‐severe psoriatic patients switched to adalimumab: results from the OPPSA study

Abstract: Adalimumab was effective at reducing PASI score over 3 years, irrespective of whether patients were biologic naïve or previously treated with a TNF-alpha or IL-12/23 inhibitor.

Cited by 17 publications

References 41 publications

Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status

Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status

Retrospective analysis of patients with psoriasis receiving biological therapy: Real‐life data

Genome‐wide association analysis of psoriasis patients treated with anti‐TNF drugs

Contact Info

Product

Resources

About